Table 4.
Costs of disease-modifying therapies per year (in €).
| Year | AVOa | REBb | BETc | EXTd | COPe | GILf | TYSg |
| 2010 | 18069.27 | 22626.46 | 17977.14 | 15528.45 | 16623.45 | N/Ah | 24625.10 |
| 2011 | 18611.35 | 23305.25 | 18516.45 | 15994.30 | 17122.15 | 26698.58i | 25363.85 |
| 2012 | 18182.19 | 22900.46 | 18132.07 | 15604.68 | 16377.93 | 25907.56 | 24586.58 |
| 2013 | 17981.00 | 22765.35 | 17815.29 | 15431.93 | 16197.00 | 22571.44 | 24214.41 |
| 2014 | 19437.31 | 24432.98 | 17601.95 | 15441.48 | 17035.61 | 18965.36 | 26194.92 |
| 2015 | 19333.96 | 24155.25 | 17517.70 | 15370.25 | 16733.32 | 20393.73 | 24280.75 |
| 2016 | 19247.42 | 23987.27 | 17384.09 | 14680.25 | 16648.48 | 21516.72 | 23321.06 |
| 2017 | 18865.10 | 23529.38 | 17047.81 | 15715.49 | 16352.26 | 20784.68 | 22902.02 |
aAVO: Avonex.
bREB: Rebif.
cBET: Betaferon.
dEXT: Extavia.
eCOP: Copaxone.
fGIL: Gilenya.
gTYS: Tysabri.
hN/A: not applicable.
iAs listed in the technology assessment report.